Sertraline hcl market

Sertraline HCl Market, by Type (25 mg, 50 mg, 100 mg and Others), by Application (Obsessive-Compulsive Disorder, Depression, Panic Disorder, Premenstrual Dysphoric Disorder, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Nov 2022
CMI5355
156 Pages
Excel & Pdf
Pharmaceutical

Summary

Sertraline hydrochloride is the hydrochloride salt of sertraline, a synthetic derivative of naphthalenamine with anti-serotoninergic and anti-depressant properties. Sertraline appears to selectively inhibit the neuronal uptake of serotonin, raising serotonin levels in the central nervous system. Sertraline hydrochloride tablets are used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (SAD), and post-traumatic stress disorder.

The global sertraline HCl market is estimated to be valued at US$ 1,385.9 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).

Figure 1. Global Sertraline HCl Market Share (%) in Terms of Value, By Application, 2022

Global Sertraline HCl Market: Drivers

Increase in the prevalence of mental disorders is expected to drive the global sertraline HCl market growth over the forecast period. For instance, according to data published by National Institute of Mental Health in January 2022, an estimated 21.0 million adults in the U.S. had at least one major depressive episode in 2020. This number represented 8.4% of all the U.S. adults in 2020.

Increasing product launches for sertraline HCl which is expected to drive the global sertraline HCl market growth during the forecast period. For instance, in November 2021, Camber Pharmaceuticals, a fully integrated international pharmaceutical company, announced that it had added sertraline hydrochloride tablets to their current portfolio, which is the generic version of Zoloft. Zoloft is an antidepressant that belongs to a group of drugs called selective serotonin reuptake inhibitors (SSRIs), Zoloft is used to treat some types of depression, premenstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), panic disorder (PD), and post traumatic stress disorder (PTSD).

Sertraline HCl Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 1,385.9 Mn
Historical Data for:	2017-2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	7.1%	2030 Value Projection:	US$ 2,407.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: 25 mg, 50 mg, 100 mg, Others By Application: Obsessive-Compulsive Disorder, Depression, Panic Disorder, Premenstrual Dysphoric Disorder, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan (a part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech
Growth Drivers:	Increasing prevalence of mental disorder Increasing product launches for sertraline HCI
Restraints & Challenges:	Product recall

Figure 2. Global Sertraline HCl Market Share (%), By Distribution Channel, 2022

Global Sertraline HCl Market– Impact of Coronavirus (COVID-19) Pandemic

The supply of raw materials required for the production of pharmaceuticals has been severely disrupted due to the forced quarantine and lack of labor during the COVID-19 pandemic. As the link between regional warehouses is not smooth, transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has negatively affected the supply chain of the global intraocular melanoma treatment market. Thus, COVID-19 pandemic is expected to have negative impact on supply chain of intraocular melanoma treatment market. According to an article published by the Exploratory Research in Clinical and Social Pharmacy journal in June 2021, a study was carried out to evaluate the impact of COVID-19 on pharmaceutical systems and supply chain in resource-limited countries in Sub-Saharan countries such as Namibia. This study revealed negative impact on availability and access of essential drugs, sanitation and hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs, which is attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs. For instance, according to a review article published by the European Pharmaceutical Review journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.

Global Sertraline HCl Market: Restraint

The major factors that hinder growth of the global sertraline HCl market include product recall. For instance, in January 2018, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, is recalling 30-count bottles of 25-mg Zoloft (sertraline hydrochloride) tablets, according to the January 10, 2018, U.S. Food and Drug Administration (FDA) Enforcement report. The company cited weight variations in the tablets that have caused superpotent and subpotent drugs.

Global Sertraline HCl Market: Key Players

Key players operating in the Sertraline HCl market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan N.V. (a Part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech

Table of Content

Table of Contents

*Browse 27 market data tables and 31 figures on "Global Sertraline HCl Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global sertraline HCl market during the forecast period (2022-2030)?

The global sertraline HCl market size is estimated to be valued at US$ 1,385.9 million in 2022 and is expected to exhibit a CAGR of 7.1% between 2022 and 2030

What are the major factors driving the market growth?

Factors such as increasing prevalence of mental disorders and increasing product launches for sertraline HCl which is expected to drive the market.

Which is the leading application segment in the market?

Depression segment is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include product recall

Which are the major players operating in the market?

Major players operating in the market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan (a part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech